专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

121. 发明授权

US5919491A Method and composition for increasing calcium uptake 失效
标题翻译：增加钙吸收的方法和组成
公开(公告)号：US5919491A
公开(公告)日：1999-07-06
申请号：US522377
申请日：1996-11-12
申请人： Prasad S. Adusumilli , Vimala Sivapragasam
发明人： Prasad S. Adusumilli , Vimala Sivapragasam
IPC分类号： A61K9/22 , A61K9/20 , A61K9/26 , A61K33/06 , A61K33/10 , A61K33/12 , A61P3/00 , A61P3/14 , A61K33/14 , A61K33/08
CPC分类号： A61K33/12 , A61K9/2054
摘要： This invention relates to a hydrophilic matrix containing a pharmaceutically acceptable calcium source for use as a calcium supplement for mammals.
摘要翻译： PCT No.PCT / US95 / 06239 Sec。 371日期：1996年11月12日 102（e）日期1996年11月12日PCT提交1995年5月12日PCT公布。公开号WO95 / 01186 日期：1995年11月23日本发明涉及含有用作哺乳动物钙补充剂的药学上可接受的钙源的亲水基质。

122. 发明授权

US5910322A Delayed release pharmaceutical formulation containing amoxycillin and potassium clavulanate 失效
标题翻译：含有阿莫西林和克拉维酸钾的延迟释放药物制剂
公开(公告)号：US5910322A
公开(公告)日：1999-06-08
申请号：US776909
申请日：1997-10-02
申请人： Ernest Lionel Gilbert Rivett , Francis Walter Grimmett , Michael William Hartnell
发明人： Ernest Lionel Gilbert Rivett , Francis Walter Grimmett , Michael William Hartnell
IPC分类号： A61K9/16 , A61K9/20 , A61K9/26 , A61K31/42 , A61K31/43 , A61K45/00
CPC分类号： A61K9/2081 , A61K31/43 , Y10S514/964 , Y10S514/965
摘要： Pharmaceutical formulations for oral administration, comprising a matrix which comprises a .beta.-lactam antibiotic optionally in combination with a .beta.-lactamase inhibitor, granules in a delayed release form dispersed within the matrix, which comprise a .beta.-lactam antibiotic optionally in combination with a .beta.-lactamase inhibitor, the overall tablet formulation including a .beta.-lactam antibiotic and a .beta.-lactamase inhibitor.
摘要翻译： PCT No.PCT / EP95 / 03151 Sec。 371 1997年10月2日第 102（e）1997年10月2日PCT PCT 1995年8月8日PCT公布。出版物WO96 / 04908 日期1996年2月22日用于口服给药的药物制剂包含基质，其包含任选与β-内酰胺酶抑制剂组合的β-内酰胺抗生素，分散在基质内的延迟释放形式的颗粒，其任选地包含β-内酰胺抗生素与β-内酰胺酶抑制剂组合，包括β-内酰胺抗生素和β-内酰胺酶抑制剂的整体片剂制剂。

123. 发明授权

US5906833A Chronological food bar 失效
标题翻译：按时间顺序排列的食物吧
公开(公告)号：US5906833A
公开(公告)日：1999-05-25
申请号：US447224
申请日：1995-05-22
申请人： Ronald M. Klatz
发明人： Ronald M. Klatz
IPC分类号： A23K1/175 , A23G3/00 , A23G3/36 , A23K1/18 , A23L1/00 , A23L1/30 , A23L1/302 , A61K9/00 , A61K9/26
CPC分类号： A23G3/366 , A23G3/368 , A23K50/00 , A23L33/10 , A23P10/28 , A61K9/0056 , A23V2002/00
摘要： A nutritional supplement contains plural parts. Each of the plural parts is chronologically appropriate for its scheduled time of consumption. The nutritional supplement is contained in a palatable base, for example, a food bar which masks any unpleasant taste or texture of the nutrient. The nutritional supplement may contain any one or several nutrients including drugs, vitamins, herbs, hormones, enzymes and/or other nutrients in chronologically appropriate dosages in each part or sub-part.
摘要翻译：营养补充剂含有多种成分。多个部分中的每一个按时间顺序适用于其预定的消费时间。营养补充剂包含在可口的基质中，例如食物棒，其掩盖营养物质的任何不愉快的味道或质地。营养补充剂可以包含任何一种或几种营养物质，包括药物，维生素，草药，激素，酶和/或其他营养物质，按时间顺序适用于每个部分或部分。

124. 发明授权

US5871774A Drug units and methods for use 失效
标题翻译：药物单位和使用方法
公开(公告)号：US5871774A
公开(公告)日：1999-02-16
申请号：US145324
申请日：1993-10-28
申请人： Jerome H. Lemelson
发明人： Jerome H. Lemelson
IPC分类号： A61K9/26 , A61K9/48 , A61K31/70 , A61K9/16 , A61K9/50 , A61K9/54 , A61K9/62
CPC分类号： A61K31/70 , A61K9/4858 , Y10S514/925 , Y10S514/926 , Y10S514/927
摘要： Medical materials for use in treating maladies in living beings, such as ulcers and other conditions of the digestive tract. In one form, a container is provided for a medication which container also contains an adhesive material which is operatively released from the container or exposed at the surface thereof upon biodegradation or dissolution of a protective coating or wall portion of the container under the effects of fluid in the digestive tract in which the container is exposed, such as by swallowing, to permit such adhesive to temporarily bond and retain the container at a select location in the digestive tract so that it may slowly release its contents thereafter to a select portion of the digestive tract. In another form, a multitude of microcapsules, each containing a small quantity of medication, is mixed with an adhesive material, such as a sulcralfate other material which may be swallowed as a tablet or dissolved in a liquid such as water. Such microcapsules are carried with the adhesive material to be bonded temporarily therewith to a select portion of the wall of the digestive tract such that, upon biodegradation or dissolution of the walls of the capsules, the contents thereof may be released over an extended period of time to cooperate with the adhesive material in protecting the lining of the digestive tract from acids secreted by the body, food roughage and the like.
摘要翻译：用于治疗生物中的疾病的医疗材料，如溃疡和消化道的其他病症。在一种形式中，为药物提供容器，该容器还包含粘合剂材料，其在容器的保护涂层或壁部分在流体的作用下生物降解或溶解时可操作地从容器中释放或暴露在其表面在容器暴露的消化道（例如吞咽）中，以允许这样的粘合剂临时粘合并将容器保持在消化道的选择位置，使得其可以缓慢地将其内容物释放到其中的选择部分消化道。在另一种形式中，每个含有少量药物的大量微胶囊与粘合剂材料混合，例如可以作为片剂吞咽或溶解在诸如水的液体中的硫酸酯其它材料。这样的微胶囊携带粘合剂材料以暂时粘合到消化道壁的选择部分，使得当胶囊的壁生物降解或溶解时，其内容物可以在延长的时间段内释放与粘合剂材料配合以保护消化道的衬里免受身体分泌的酸，食物粗饲料等。

125. 发明授权

US5851551A Sustained-release matrices for dental application 失效
公开(公告)号：US5851551A
公开(公告)日：1998-12-22
申请号：US262961
申请日：1994-06-21
申请人： Mingchih M. Tseng , Carl M. Philbrook
发明人： Mingchih M. Tseng , Carl M. Philbrook
IPC分类号： A46B15/00 , A46B11/00 , A61C17/00 , A61K8/43 , A61K8/81 , A61K8/86 , A61K9/22 , A61K31/74 , A61M31/00 , A61Q11/00 , A61K9/26 , A61K7/16 , A61K7/22
CPC分类号： A61Q11/00 , A46B11/00 , A46B15/001 , A61K8/43 , A61K8/8135 , A61K8/86 , A61K2800/43
摘要： A sustained-release matrix for dental application includes either an anti-microbial agent or a colorant that is released from the matrix when the matrix contacts water. The preferred matrices include a water-soluble polymer and a water-insoluble support resin.

126. 发明授权

US5843478A Lanperisone formulation 失效
标题翻译：蓝皮松制剂
公开(公告)号：US5843478A
公开(公告)日：1998-12-01
申请号：US721552
申请日：1996-09-26
申请人： Hiroshi Ohtaki , Rie Joshita
发明人： Hiroshi Ohtaki , Rie Joshita
IPC分类号： A61K9/20 , A61K9/26 , A61K31/40 , A61K9/50
CPC分类号： A61K9/2077 , A61K31/40
摘要： A lanperisone hydrochloride compression-molded formulation comprising the first granules containing lanperisone hydrochloride and the second granules containing substantially no lanperisone hydrochloride but at least one pharmaceutical additive(s) selected from the group consisting of sugars, crystalline celluloses and cellulose derivatives is an excellent formulation which has a high storage stability because the decomposition of lanperisone hydrochloride is suppressed.
摘要翻译：一种盐酸兰哌磺酸盐压制成型制剂，其包含含有盐酸氟哌兰定的第一颗粒和基本上不含盐酸氟哌兰但含有至少一种选自糖，结晶纤维素和纤维素衍生物的药物添加剂的第二颗粒，具有高的储存稳定性，因为抑制了盐酸兰吡酮的分解。

127. 发明授权

US5840329A Pulsatile drug delivery system 失效
标题翻译：脉动药物输送系统
公开(公告)号：US5840329A
公开(公告)日：1998-11-24
申请号：US857105
申请日：1997-05-15
申请人： Jane Pei-Fan Bai
发明人： Jane Pei-Fan Bai
IPC分类号： A61K9/16 , A61K9/20 , A61K9/26 , A61K9/50 , A61K9/56 , A61K9/58 , A61K9/60 , A61K9/62
CPC分类号： A61K9/5084 , A61K9/2081 , A61K9/1676 , A61K9/5078
摘要： A pulsatile drug delivery system comprising of a plurality of particles is able to deliver drug in any desired patterns. A plurality of particles with multi-layer core capable of short-pulse release interlaced with long-duration release is designed for delivery of multi-agents simultaneously or sequentially, or single agent, according to a pre-programmed profile.
摘要翻译：包含多个颗粒的脉动药物递送系统能够以任何所需的模式递送药物。多个具有能够短时间释放的具有长时间释放的多层核心的颗粒被设计成根据预编程的轮廓同时或顺序地递送多个试剂或单个试剂。

128. 发明授权

US5837284A Delivery of multiple doses of medications 失效
公开(公告)号：US5837284A
公开(公告)日：1998-11-17
申请号：US892190
申请日：1997-07-14
申请人： Atul M. Mehta , Andrew L. Zeitlin , Maghsoud M. Dariani
发明人： Atul M. Mehta , Andrew L. Zeitlin , Maghsoud M. Dariani
IPC分类号： A61K9/16 , A61K9/20 , A61K9/26 , A61K9/28 , A61K9/50 , A61K9/54 , A61K31/445 , A61K31/4458 , A61P25/00 , A61P25/28 , C07D211/34 , C12P17/12 , C12P41/00 , A61K9/56 , A61K9/22 , A61K9/58 , A61K31/21
CPC分类号： A61K9/2886 , A61K31/445 , A61K31/4458 , A61K9/1676 , A61K9/5078 , A61K9/5084 , C07D211/34 , C12P17/12 , C12P41/006 , A61K9/2081 , A61K9/5026 , A61K9/5047
摘要： Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.

129. 发明授权

US5798120A Enteric granule-containing tablets 失效
标题翻译：含肠溶颗粒的片剂
公开(公告)号：US5798120A
公开(公告)日：1998-08-25
申请号：US624510
申请日：1996-04-05
申请人： Matsushita Tomohisa , Hashimoto Mitsuo
发明人： Matsushita Tomohisa , Hashimoto Mitsuo
IPC分类号： A61K9/20 , A61K9/26 , A61K9/52 , A61K9/32
CPC分类号： A61K9/2009 , A61K9/2081
摘要： The present invention relates to enteric granule-containing tablets which are prepared by tabletting a mixture of enteric granules containing an active agent, with one or a combination of 2 or more compounds selected from synthetic hydrotalcite, dried aluminum hydroxide gel, aluminum hydroxide/sodium hydrogen carbonate coprecipitate, alumina hydroxide/magnesium, synthetic aluminum silicate and dihydroxyaluminumamino acetate. The invention provides high-strength tablets which are formulated with specific excipients which allow a higher enteric granule content, faster dispersion in the enteric granules, no loss of drug elution properties or acid resistance of the enteric granules upon tabletting, with less damage in the coating and low weight variation of the tablets during tabletting, as compared to tablets containing coated granules according to the prior art. This technique for achieving a high enteric granule content has additional merits including better versatility of dosages due to the small size of the tablets, and further applications for other drug agents.
摘要翻译： PCT No.PCT / JP94 / 01675 Sec。 371日期：1996年4月5日 102（e）日期1996年4月5日PCT 1994年10月6日PCT PCT。 WO95 / 10264 PCT出版物日期：1995年04月20日本发明涉及通过将含有活性剂的肠溶颗粒混合物与一种或两种以上选自合成水滑石，干燥氢氧化铝凝胶，氢氧化铝/碳酸氢钠共沉淀物，氢氧化铝/镁，合成硅酸铝和二羟基铝氨基乙酸酯。本发明提供了与特定赋形剂一起配制的高强度片剂，其允许更高的肠溶颗粒含量，肠溶颗粒中更快的分散性，在压片时不会丧失药物洗脱性质或肠溶颗粒的耐酸性，涂层损伤较少与片剂相比，片剂在片剂中的重量变化较小。用于实现高肠溶颗粒含量的这种技术具有额外的优点，包括由于片剂的小尺寸而导致的剂量的更好的通用性，以及其它药物的进一步应用。

130. 发明授权

US5780055A Cushioning beads and tablet comprising the same capable of forming a suspension 失效
标题翻译：包括能形成悬浮液的缓冲珠和片剂
公开(公告)号：US5780055A
公开(公告)日：1998-07-14
申请号：US709415
申请日：1996-09-06
申请人： Yacoub S. Habib , Ralph Shangraw , Larry L. Augsburger
发明人： Yacoub S. Habib , Ralph Shangraw , Larry L. Augsburger
IPC分类号： A61K9/20 , A61K9/26 , B01J13/02
CPC分类号： A61K9/2081 , B01J13/02 , A61K9/2054
摘要： Cushioning beads comprising microcrystalline cellulose and a disintegrant (preferably croscarmellose sodium) are disclosed. The cushioning beads are prepared by extrusion-spheronization, followed by freeze-drying. Also disclosed, are water-dispersible tablets having high tensile strength, comprising the cushioning beads and biologically active ingredient-loaded beads, wherein optionally, the tablets can contain a viscosity enhancer in the form of separate beads, or as a component of the biologically active ingredient-loaded beads such that viscosity is rapidly generated when the tablets come in contact with water, and a homogenous suspension is formed, which can be easily swallowed by children and the elderly, with minimal effect of the biologically active ingredient release properties. The tablets are useful for sustained delivery of large doses of biologically active ingredients where swallowing of a large tablet or capsule poses a problem.
摘要翻译：公开了包含微晶纤维素和崩解剂（优选交联羧甲纤维素钠）的缓冲珠。缓冲珠通过挤出滚圆法制备，然后冷冻干燥。还公开了具有高拉伸强度的水分散性片剂，其包含缓冲珠粒和生物活性成分负载珠粒，其中任选地，片剂可以含有分离珠粒形式的粘度增强剂，或作为生物活性成分的组分成分负载的珠子，使得当片剂与水接触时，粘度迅速产生，并且形成均匀的悬浮液，其可以容易地被儿童和老年人吞咽，同时具有最小的生物活性成分释放性质的影响。片剂可用于持续递送大剂量的生物活性成分，其中吞咽大片剂或胶囊引起问题。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式